Lantheus Holdings Contact | Compliance | Reimbursement | Supply Updates | Supplier Link
Investor Relations


Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“Lantheus”), which is a global leader in developing, manufacturing, selling and distributing innovative diagnostic image agents and products.

Our expertise in discovering, developing and commercializing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus has a rich heritage and expertise in cardiovascular imaging and nuclear medicine, having pioneered many of the most significant products used in medical imaging.

Our current imaging agents primarily assist in the diagnosis of heart, vascular and other diseases using nuclear imaging, echocardiography and magnetic resonance imaging (MRI) technologies. We have a pipeline of next-generation and first-in-class products using Positron Emission Tomography (PET) and MRI technologies.

Our vision is to be the leading provider of innovative medical imaging solutions to improve human life. We are committed to developing next generation and first-in-class imaging agents to assist physicians in the diagnosis of heart, vascular and other diseases.

With direct operations in the United States, Puerto Rico, Canada and Australia, we have a long and distinguished history of developing and commercializing innovative market-changing products.

Recent News

Lantheus Holdings Announces First Commercial Shipment of Xenon 133 Supplied by Institute for Radioelements (IRE)

Commercial Availability of IRE-Sourced Xenon 133 Demonstrates Commitment to Secure and Provide Continuous Supply to U.S. Medical Market through 2016 and Beyond

NORTH BILLERICA, Mass., June 30, 2016Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced the first commercial shipment of Xenon Xe 133 Gas (Xenon 133) using unprocessed radiochemical Xenon 133 supplied by the Institute for Radioelements (IRE) in Belgium. The commercial availability of Xenon 133 sourced from IRE supports Lantheus’ commitment to ensuring the medical community has continued reliable access to Xenon 133 through 2016 and beyond. Lantheus is the market leader in the U.S. for the supply of finished vials of Xenon 133, an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and imaging the lungs

click here for the press release

Company Spotlight

Webcast Image

Jefferies 2016 Healthcare Conference
Tuesday, June 7, 2016 at 2:00 p.m. ET

Webcast Image

Q1 2016 Lantheus Holdings Earnings Conference Call
Tuesday, May 3, 2016 at 4:30 p.m. ET


© 2015 Lantheus Medical Imaging, Inc. Contact | Compliance | Reimbursement | Supply Updates | Supplier Link | Site Map